MX2018013941A - Terapia de combinacion con inhibidores de notch y pd-1 o pd-l1. - Google Patents
Terapia de combinacion con inhibidores de notch y pd-1 o pd-l1.Info
- Publication number
- MX2018013941A MX2018013941A MX2018013941A MX2018013941A MX2018013941A MX 2018013941 A MX2018013941 A MX 2018013941A MX 2018013941 A MX2018013941 A MX 2018013941A MX 2018013941 A MX2018013941 A MX 2018013941A MX 2018013941 A MX2018013941 A MX 2018013941A
- Authority
- MX
- Mexico
- Prior art keywords
- cancer
- lymphoblastic leukemia
- oxo
- carcinoma
- treating
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
- A61K31/542—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2827—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Genetics & Genomics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Endocrinology (AREA)
- Engineering & Computer Science (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662339363P | 2016-05-20 | 2016-05-20 | |
| PCT/US2017/032790 WO2017200969A1 (en) | 2016-05-20 | 2017-05-16 | Combination therapy with notch and pd-1 or pd-l1 inhibitors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2018013941A true MX2018013941A (es) | 2019-03-21 |
Family
ID=58772978
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2018013941A MX2018013941A (es) | 2016-05-20 | 2017-05-16 | Terapia de combinacion con inhibidores de notch y pd-1 o pd-l1. |
Country Status (15)
| Country | Link |
|---|---|
| US (2) | US10688104B2 (enExample) |
| EP (1) | EP3458091B1 (enExample) |
| JP (1) | JP7194022B2 (enExample) |
| KR (1) | KR102463617B1 (enExample) |
| CN (2) | CN115845070A (enExample) |
| AU (1) | AU2017268187A1 (enExample) |
| BR (1) | BR112018073673A2 (enExample) |
| CA (1) | CA3025024A1 (enExample) |
| ES (1) | ES2904880T3 (enExample) |
| IL (1) | IL263110B (enExample) |
| MA (1) | MA45025A (enExample) |
| MX (1) | MX2018013941A (enExample) |
| SG (1) | SG11201810268YA (enExample) |
| WO (1) | WO2017200969A1 (enExample) |
| ZA (1) | ZA201807585B (enExample) |
Families Citing this family (33)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI609687B (zh) | 2015-04-14 | 2018-01-01 | 美國禮來大藥廠 | 平滑肌肉瘤之標靶性治療 |
| MX383464B (es) | 2015-07-13 | 2025-03-14 | Cytomx Therapeutics Inc | Anticuerpos anti-pd-1, anticuerpos anti-pd-1 activables, y métodos de uso de los mismos. |
| MX380779B (es) | 2016-04-12 | 2025-03-12 | Lilly Co Eli | Terapia combinatoria con inhibidores notch y cdk4/6 |
| US11564929B2 (en) | 2016-04-12 | 2023-01-31 | Eli Lilly And Company | Combination therapy with Notch and PI3K/mTOR inhibitors for use in treating cancer |
| EP3458091B1 (en) | 2016-05-20 | 2021-11-17 | Eli Lilly and Company | Combination therapy with notch and pd-1 or pd-l1 inhibitors |
| EP3525796A1 (en) | 2016-10-12 | 2019-08-21 | Eli Lilly and Company | Targeted treatment of mature t-cell lymphoma |
| IL268349B2 (en) | 2017-02-17 | 2024-08-01 | Hutchinson Fred Cancer Res | Combination therapies for treatment of bcma-related cancers and autoimmune disorders |
| AU2018359907A1 (en) | 2017-11-06 | 2020-05-07 | Fred Hutchinson Cancer Center | Combination of a cell therapy and a gamma secretase inhibitor |
| EP3823669A1 (en) * | 2017-12-18 | 2021-05-26 | Debiopharm International SA | Combination of an agonist anti-pd-1 antibody with a gnrh agonist or antagonist to treat cancer |
| EP4051260A4 (en) * | 2019-10-28 | 2023-12-06 | Enzychem Lifesciences Corporation | METHODS AND COMPOSITIONS FOR TREATING CANCER |
| CA3216896A1 (en) * | 2021-04-28 | 2022-11-03 | Ming-Tain Lai | Combination therapy by using akr1c3-activated compound with immune checkpoint inhibitor |
| KR20260019479A (ko) | 2023-05-04 | 2026-02-10 | 레볼루션 메디슨즈, 인크. | Ras 관련 질환 또는 장애를 위한 병용 요법 |
| CN121889155A (zh) | 2023-08-07 | 2026-04-17 | 锐新医药公司 | 用于治疗ras蛋白相关疾病或病症的rmc-6291 |
| AU2024360465A1 (en) | 2023-10-12 | 2026-04-09 | Revolution Medicines, Inc. | Macrocyclic ras inhibitors |
| WO2025171296A1 (en) | 2024-02-09 | 2025-08-14 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2025240847A1 (en) | 2024-05-17 | 2025-11-20 | Revolution Medicines, Inc. | Ras inhibitors |
| US20250375445A1 (en) | 2024-06-07 | 2025-12-11 | Revolution Medicines, Inc. | Methods of treating a ras protein-related disease or disorder |
| WO2025265060A1 (en) | 2024-06-21 | 2025-12-26 | Revolution Medicines, Inc. | Therapeutic compositions and methods for managing treatment-related effects |
| WO2026006747A1 (en) | 2024-06-28 | 2026-01-02 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2026015790A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Methods of treating a ras related disease or disorder |
| WO2026015825A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Use of ras inhibitor for treating pancreatic cancer |
| WO2026015801A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Methods of treating a ras related disease or disorder |
| WO2026015796A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Methods of treating a ras related disease or disorder |
| WO2026050446A1 (en) | 2024-08-29 | 2026-03-05 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2026072904A2 (en) | 2024-09-26 | 2026-04-02 | Revolution Medicines, Inc. | Compositions and methods for treating lung cancer |
| WO2026090116A2 (en) | 2024-10-21 | 2026-04-30 | Revolution Medicines, Inc. | Ras inhibitors |
| US20260108528A1 (en) | 2024-10-22 | 2026-04-23 | Revolution Medicines, Inc. | Methods of treating a ras protein-related disease or disorder |
| WO2026090245A1 (en) | 2024-10-22 | 2026-04-30 | Revolution Medicines, Inc. | Use of ras inhibitors for treating cancer |
| WO2026106912A1 (en) | 2024-11-12 | 2026-05-21 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2026112260A1 (en) | 2024-11-21 | 2026-05-28 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2026122764A2 (en) | 2024-12-06 | 2026-06-11 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2026128688A2 (en) | 2024-12-13 | 2026-06-18 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2026161839A1 (en) | 2025-01-27 | 2026-07-30 | Revolution Medicines, Inc. | Ras inhibitors |
Family Cites Families (50)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ZA9711537B (en) | 1996-12-23 | 1998-06-25 | Athena Neurosciences Inc Eli L | Cycloalkyl, lactam, lactone and related compounds, pharmaceutical compositions comprising same, and methods for inhibiting ß-amyloid peptide release and/or its synthesis by use of such compounds. |
| WO2000020576A2 (en) | 1998-10-02 | 2000-04-13 | The Government Of The United States Of America, As Represented By The Secretary, Dept. Of Health And Human Services, The National Institutes Of Health | Methods and compositions for inducing differentiation and apotosis in cells that overexpess the notch protein |
| ES2367430T3 (es) | 2002-12-23 | 2011-11-03 | Wyeth Llc | Anticuerpos contra pd-1 y sus usos. |
| GB0303663D0 (en) * | 2003-02-18 | 2003-03-19 | Lorantis Ltd | Assays and medical treatments |
| EP3530736A3 (en) | 2005-05-09 | 2019-11-06 | ONO Pharmaceutical Co., Ltd. | Human monoclonal antibodies to programmed death 1 (pd-1) and methods for treating cancer using anti-pd-1 antibodies alone or in combination with other immunotherapeutics |
| KR101704734B1 (ko) | 2005-07-01 | 2017-02-09 | 이. 알. 스퀴부 앤드 선즈, 엘.엘.씨. | 예정 사멸 리간드 1 (피디-엘1)에 대한 인간 모노클로날 항체 |
| WO2007004743A1 (en) | 2005-07-05 | 2007-01-11 | Fujifilm Corporation | Copolymer and polymerizable composition |
| DE102006002966A1 (de) * | 2006-01-21 | 2007-07-26 | Schaeffler Kg | Laufscheibe mit integrierter Wälzkörperlaufbahn |
| US8633179B2 (en) | 2007-03-13 | 2014-01-21 | The Trustees Of Columbia University In The City Of New York | Synergistic interaction of NOTCH-1 inhibitors with glucocorticoids |
| EP2139487B1 (en) | 2007-03-28 | 2015-11-11 | Pharmacyclics LLC | Inhibitors of bruton's tyrosine kinase |
| PT2170959E (pt) | 2007-06-18 | 2014-01-07 | Merck Sharp & Dohme | Anticorpos para o receptor humano de morte programada pd-1 |
| KR101136260B1 (ko) | 2007-08-14 | 2012-04-19 | 일라이 릴리 앤드 캄파니 | 감마-세크레타제 억제제로서의 아제핀 유도체 |
| US20090181944A1 (en) | 2008-01-11 | 2009-07-16 | John Frederick Boylan | Method for cancer therapy |
| US8168757B2 (en) | 2008-03-12 | 2012-05-01 | Merck Sharp & Dohme Corp. | PD-1 binding proteins |
| EA201500417A1 (ru) | 2008-08-25 | 2015-11-30 | Эмплиммьюн, Инк. | Композиции антагонистов pd-1 и способы применения |
| MX356367B (es) | 2008-12-09 | 2018-05-25 | Genentech Inc | Anticuerpos anti-pd-l1 y su uso para mejorar la funcion de celulas t. |
| PA8852901A1 (es) | 2008-12-22 | 2010-07-27 | Lilly Co Eli | Inhibidores de proteina cinasa |
| WO2010089411A2 (en) | 2009-02-09 | 2010-08-12 | Universite De La Mediterranee | Pd-1 antibodies and pd-l1 antibodies and uses thereof |
| EP2470054B1 (de) | 2009-08-26 | 2013-12-04 | FrXsh AG | Vorrichtung und verfahren zum mischen von mischgut |
| WO2011060051A1 (en) | 2009-11-12 | 2011-05-19 | University Of Massachusetts | Methods for treating glioblastoma |
| EP3279215B1 (en) | 2009-11-24 | 2020-02-12 | MedImmune Limited | Targeted binding agents against b7-h1 |
| CN102085372A (zh) | 2009-12-04 | 2011-06-08 | 中国医学科学院基础医学研究所 | Notch通路抑制剂用于治疗mTOR活化导致的肿瘤的用途 |
| US9163087B2 (en) * | 2010-06-18 | 2015-10-20 | The Brigham And Women's Hospital, Inc. | Bi-specific antibodies against TIM-3 and PD-1 for immunotherapy in chronic immune conditions |
| JO3003B1 (ar) | 2011-01-14 | 2016-09-05 | Lilly Co Eli | مركب أيميدازو [4، 5 -c ] كينولين-2- واحد واستخدامه كمثبط كيناز PI3/mtor |
| AR087107A1 (es) | 2011-07-27 | 2014-02-12 | Lilly Co Eli | Compuesto inhibidor de la señalizacion de la trayectoria notch |
| BR112014002353B1 (pt) * | 2011-08-01 | 2022-09-27 | Genentech, Inc | Usos de antagonistas de ligação do eixo pd-1 e inibidores de mek, composições farmacêuticas, e kit |
| BR112014012819B1 (pt) | 2011-11-28 | 2022-08-16 | Merck Patent Gmbh | Anticorpo anti-pd-l1 ou fragmento de ligação ao antígeno do mesmo e composição |
| WO2014193898A1 (en) * | 2013-05-31 | 2014-12-04 | Merck Sharp & Dohme Corp. | Combination therapies for cancer |
| US9698876B2 (en) | 2013-07-23 | 2017-07-04 | Telefonaktiebolaget Lm Ericsson (Publ) | Transmission mode allocation in LTE networks |
| AU2014309199B2 (en) * | 2013-08-20 | 2018-04-19 | Merck Sharp & Dohme Llc | Treating cancer with a combination of a PD-1 antagonist and dinaciclib |
| GB201317929D0 (en) | 2013-10-10 | 2013-11-27 | Ucl Business Plc | Chimeric antigen receptor |
| WO2015117164A1 (en) * | 2014-02-03 | 2015-08-06 | Memorial Sloan-Kettering Cancer Center | Tumor-associated macrophages and methods and compositions for targeting cancer therapy and identifying potential responders |
| US10092645B2 (en) * | 2014-06-17 | 2018-10-09 | Medimmune Limited | Methods of treatment with antagonists against PD-1 and PD-L1 in combination with radiation therapy |
| EP3166627A1 (en) | 2014-07-11 | 2017-05-17 | Genentech, Inc. | Notch pathway inhibition |
| AU2015292744C1 (en) | 2014-07-21 | 2021-01-21 | Novartis Ag | Treatment of cancer using humanized anti-BCMA chimeric antigen receptor |
| US9465158B2 (en) * | 2014-09-04 | 2016-10-11 | National Taiwan Normal University | Light-guide coupler for modulating angular and spatial distributions of light source |
| EP3191126B1 (en) * | 2014-09-13 | 2020-05-13 | Novartis AG | Combination therapies of alk inhibitors |
| RU2716716C2 (ru) * | 2014-10-27 | 2020-03-16 | Фред Хатчинсон Кэнсер Рисёрч Сентер | Композиции и способы для бустинга эффективности адоптивной клеточной иммунотерапии |
| EP3212233B1 (en) * | 2014-10-31 | 2020-06-24 | Oncomed Pharmaceuticals, Inc. | Combination therapy for treatment of disease |
| HRP20210582T1 (hr) | 2014-12-05 | 2021-09-03 | Memorial Sloan Kettering Cancer Center | Antitijela koja ciljaju antigen sazrijevanja b-stanice i postupci uporabe |
| US20180140602A1 (en) | 2015-04-07 | 2018-05-24 | Novartis Ag | Combination of chimeric antigen receptor therapy and amino pyrimidine derivatives |
| TWI609687B (zh) | 2015-04-14 | 2018-01-01 | 美國禮來大藥廠 | 平滑肌肉瘤之標靶性治療 |
| EP3324965A4 (en) | 2015-07-24 | 2019-07-03 | Oncotracker, Inc. | Gamma secretase modulators for the treatment of immune system dysfunction |
| US11564929B2 (en) | 2016-04-12 | 2023-01-31 | Eli Lilly And Company | Combination therapy with Notch and PI3K/mTOR inhibitors for use in treating cancer |
| MX380779B (es) | 2016-04-12 | 2025-03-12 | Lilly Co Eli | Terapia combinatoria con inhibidores notch y cdk4/6 |
| EP3458091B1 (en) | 2016-05-20 | 2021-11-17 | Eli Lilly and Company | Combination therapy with notch and pd-1 or pd-l1 inhibitors |
| JP2019526632A (ja) | 2016-08-31 | 2019-09-19 | イーライ リリー アンド カンパニー | 固形腫瘍の治療のための投薬レジメン |
| EP3525796A1 (en) | 2016-10-12 | 2019-08-21 | Eli Lilly and Company | Targeted treatment of mature t-cell lymphoma |
| EP3615055A1 (en) | 2017-04-28 | 2020-03-04 | Novartis AG | Cells expressing a bcma-targeting chimeric antigen receptor, and combination therapy with a gamma secretase inhibitor |
| AU2018359907A1 (en) | 2017-11-06 | 2020-05-07 | Fred Hutchinson Cancer Center | Combination of a cell therapy and a gamma secretase inhibitor |
-
2017
- 2017-05-16 EP EP17726073.4A patent/EP3458091B1/en active Active
- 2017-05-16 AU AU2017268187A patent/AU2017268187A1/en not_active Abandoned
- 2017-05-16 SG SG11201810268YA patent/SG11201810268YA/en unknown
- 2017-05-16 CN CN202211692364.1A patent/CN115845070A/zh active Pending
- 2017-05-16 US US16/301,360 patent/US10688104B2/en active Active
- 2017-05-16 CN CN201780044786.9A patent/CN109475629A/zh active Pending
- 2017-05-16 BR BR112018073673-2A patent/BR112018073673A2/pt not_active Application Discontinuation
- 2017-05-16 ES ES17726073T patent/ES2904880T3/es active Active
- 2017-05-16 CA CA3025024A patent/CA3025024A1/en active Pending
- 2017-05-16 MX MX2018013941A patent/MX2018013941A/es unknown
- 2017-05-16 KR KR1020187036486A patent/KR102463617B1/ko not_active Expired - Fee Related
- 2017-05-16 MA MA045025A patent/MA45025A/fr unknown
- 2017-05-16 JP JP2018560759A patent/JP7194022B2/ja active Active
- 2017-05-16 IL IL263110A patent/IL263110B/en unknown
- 2017-05-16 WO PCT/US2017/032790 patent/WO2017200969A1/en not_active Ceased
-
2018
- 2018-11-12 ZA ZA2018/07585A patent/ZA201807585B/en unknown
-
2020
- 2020-05-08 US US16/870,853 patent/US11826317B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| US10688104B2 (en) | 2020-06-23 |
| US20220008432A1 (en) | 2022-01-13 |
| ES2904880T3 (es) | 2022-04-06 |
| JP7194022B2 (ja) | 2022-12-21 |
| EP3458091A1 (en) | 2019-03-27 |
| EP3458091B1 (en) | 2021-11-17 |
| BR112018073673A2 (pt) | 2019-02-26 |
| SG11201810268YA (en) | 2018-12-28 |
| WO2017200969A1 (en) | 2017-11-23 |
| IL263110B (en) | 2022-07-01 |
| US20190192531A1 (en) | 2019-06-27 |
| US11826317B2 (en) | 2023-11-28 |
| MA45025A (fr) | 2019-03-27 |
| IL263110A (en) | 2018-12-31 |
| CA3025024A1 (en) | 2017-11-23 |
| KR102463617B1 (ko) | 2022-11-03 |
| KR20190008913A (ko) | 2019-01-25 |
| CN115845070A (zh) | 2023-03-28 |
| AU2017268187A1 (en) | 2018-11-29 |
| JP2019516733A (ja) | 2019-06-20 |
| ZA201807585B (en) | 2024-09-25 |
| CN109475629A (zh) | 2019-03-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ZA201807585B (en) | Combination therapy with notch and pd-1 or pd-l1 inhibitors | |
| JP2019516733A5 (enExample) | ||
| ZA202309638B (en) | Pyrimidine-fused cyclic compound, preparation method therefor and use thereof | |
| TN2020000001A1 (en) | Carboxamides as modulators of sodium channels | |
| PL3883579T3 (pl) | Terapia skojarzona obejmująca inhibitor kras-g12c i jeden lub więcej dodatkowych farmaceutycznie aktywnych środków w leczeniu nowotworów | |
| MY199967A (en) | Combinations of lsd1 inhibitors for use in the treatment of solid tumors | |
| RU2018102078A (ru) | Комбинированная терапия противоопухолевым алкалоидом | |
| MX380779B (es) | Terapia combinatoria con inhibidores notch y cdk4/6 | |
| MX2014010590A (es) | Terapia de combinacion para trastornos proliferativos. | |
| WO2009099634A3 (en) | Picoplatin and amrubicin to treat lung cancer | |
| MX380780B (es) | TERAPIA COMBINATORIA CON INHIBIDORES NOTCH Y PI3K/mTOR. | |
| MX2020008258A (es) | Formulaciones pediátricas de niraparib y métodos de tratamiento pediátricos. | |
| IN2014DN11099A (enExample) | ||
| JOP20200015A1 (ar) | توليفة علاجية من مثبط كيناز تيروسين egfr من الجيل الثالث ومثبط كيناز يعتمد على سيكلين | |
| MX2022009612A (es) | Combinacion de bi853520 con farmacos quimioterapeuticos. | |
| PH12018502422A1 (en) | Nanoliposomal irinotecan for use in treating small cell lung cancer | |
| MX2021007477A (es) | Terapia de combinacion con un inhibidor de raf y un inhibidor de cdk4/6 para utilizar en el tratamiento del cancer. | |
| MX2019002121A (es) | Tratamiento conjunto para tratar el cancer de pancreas. | |
| EP4445914A4 (en) | PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF TUMORS AND USE | |
| MX358501B (es) | Combinación farmacéutica de sinergia para el tratamiento del carcinoma de célula escamosa de cabeza y cuello. | |
| NZ596226A (en) | Antitumor combination including cabazitaxel and capecitabine | |
| PH12018502360A1 (en) | 2-anilinopyrimidine derivatives as therapeutic agents for treatment of brain cancers | |
| JP2011500723A5 (enExample) | ||
| RU2010119922A (ru) | Усовершенствованное противоопухолевое лечение | |
| WO2014115859A3 (ja) | 分子標的併用腫瘍治療・予防薬 |